Skip to main content

Table 1 Baseline characteristics of 103 patients

From: Biological characteristics and treatment outcomes of metastatic or recurrent neuroendocrine tumors: tumor grade and metastatic site are important for treatment strategy

Characteristic

Frequency

%

 

Median (years)

54 (range, 22-78)

Age

<60

63

61.2

 

≥ 60

40

38.8

Sex

Male

58

56.3

 

Female

45

43.7

 

Absent

92

89.3

Carcinoid symptom

Present

5

4.9

 

Unavailable

6

5.8

 

Pancreas

26

25.2

 

GI tract

27

26.2

 

   Foregut

11

10.7

 

   Midgut

1

1.0

Origin

   Hindgut

15

14.6

 

Lung

2

1.9

 

Etc.*

28

27.2

 

Unknown

20

19.4

Initial metastatic site

Liver

50

74.6

 

Bone

12

17.9

 

Lung

12

17.9

 

Brain

3

4.5

 

Lymph node

20

29.9

 

Etc.

10

14.9

Recurrent site

Liver

15

41.7

 

Bone

16

44.4

 

Lung

1

2.8

 

Brain

1

2.8

 

Lymph node

15

41.7

 

Etc.

3

8.3

 

Local

21

21.4

Prior stage

Regional

15

14.6

 

Distant

67

65.0

 

1

34

33.0

 

2

1

1.0

Grade

3

15

14.6

 

Large

9

8.7

 

Small

7

6.8

 

Unclassified

25

24.3

 

Unavailable

12

11.7

  

Median (range)

23.0 (2.6-1324.6)

 

24-hour urine 5-HIAA (μmol/day)†

<31.4 (reference range)

15

71.4

Biomarkers

 

≥ 31.4

6

28.6

  

Median (range)

1.6 (0.4-23.1)

 

Serum NSE (nmol/l)‡

<1.0 (reference range)

12

36.4

  

≥ 1.0

21

63.6

  1. GI, gastrointestinal; 5-HIAA, 5-hydroxyindoleacetic acid; NSE, neuron-specific enolase
  2. * The biliary tract (5 cases), thymus (4), uterus (4), mediastinum (3), oral cavity (2), skin (2), trachea (1), liver (1), kidney (1), pelvis (1), prostate (1), bladder (1), nasal cavity (1), and orbit (1)
  3. † Available data: 21
  4. ‡ Available data: 33
Back to article page

BMC Cancer

ISSN: 1471-2407

Contact us